DRG Market Assessment 보고서

Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…

Thyroid eye disease (TED) is a rare, vision-threatening autoimmune disorder that typically begins with an active inflammatory phase before progressing to a chronic stage. Amgen’s Tepezza is…

Autism spectrum disorder (ASD) is a complex, heterogeneous, neurodevelopmental disorder that involves significant social, communicational, and behavioral challenges. Behavioral and developmental…

Due to the rising rates of antimicrobial resistance, antibiotics with activity against drug-resistant gram-negative pathogens are essential. Antibiotics such as carbapenems, which have historically…

The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…

In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…

In 2024, sales of branded biologics for endocrinology indications (insulins and antiresorptive analogues) exceeded $22 billion in the major pharmaceutical markets under study (United States, EU5,…

The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options…

In 2024, sales of branded biologics in immunology exceeded $65 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in the major market in…

The acute lymphoblastic leukemia (ALL) therapy market is entering a dynamic period of growth driven by the introduction of targeted agents and nextgeneration cell therapies. Widely used…

In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…

In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $160 billion in the major…